With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34946-82-2,Copper(II) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.
General procedure: Representative procedure for 17: A Schlenk tube was charged with 2 (400mg, 2.03mmol), dry THF (10mL), anhydrous cobalt(II) chloride and a stirring bar. In a separate Schlenk tube, a solution of lithium diisopropylamide (LDA) was prepared in THF (25mL) from diisopropylamine (700muL, 5.0 mmol) and n-butyl lithium (3.15mL of a 1.6M solution in hexane, 5.0 mmol). The LDA-solution was added under protection from air to the solution of 2 and CoCl2. After the mixture has been stirred overnight, all volatile materials were removed on a vacuum line. The Schlenk vessel was transferred into the glove-box and the dark colored solid residue was dissolved in a small volume of dry dichloromethane. Layering the solution with dry n-hexane afforded brown single crystals of the product.
34946-82-2 Copper(II) trifluoromethanesulfonate 2734996, acopper-catalyst compound, is more and more widely used in various.
Reference£º
Article; Graser, Markus; Kopacka, Holger; Wurst, Klaus; Mueller, Thomas; Bildstein, Benno; Inorganica Chimica Acta; vol. 401; (2013); p. 38 – 49;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”